BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Charabati M, Rabanel JM, Ramassamy C, Prat A. Overcoming the Brain Barriers: From Immune Cells to Nanoparticles. Trends Pharmacol Sci 2020;41:42-54. [PMID: 31839374 DOI: 10.1016/j.tips.2019.11.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Y, Yue P, Peng Y, Sun Y, Chen X, Zhao Z, Han B. Recent advances in drug delivery systems for targeting brain tumors. Drug Deliv 2023;30:1-18. [PMID: 36597214 DOI: 10.1080/10717544.2022.2154409] [Reference Citation Analysis]
2 Mendanha D, Vieira de Castro J, Casanova MR, Gimondi S, Ferreira H, Neves NM. Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy. Nanomedicine 2023;49:102663. [PMID: 36773669 DOI: 10.1016/j.nano.2023.102663] [Reference Citation Analysis]
3 Wang W, Wu F, Mohammadniaei M, Zhang M, Li Y, Sun Y, Tang BZ. Genetically edited T-cell membrane coated AIEgen nanoparticles effectively prevents glioblastoma recurrence. Biomaterials 2023;293:121981. [PMID: 36580721 DOI: 10.1016/j.biomaterials.2022.121981] [Reference Citation Analysis]
4 Charabati M, Zandee S, Fournier AP, Tastet O, Thai K, Zaminpeyma R, Lécuyer M, Bourbonnière L, Larouche S, Klement W, Grasmuck C, Tea F, Zierfuss B, Filali-mouhim A, Moumdjian R, Bouthillier A, Cayrol R, Peelen E, Arbour N, Larochelle C, Prat A. MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes. Brain 2022. [DOI: 10.1093/brain/awac389] [Reference Citation Analysis]
5 Wu J, Ma L, Sun D, Zhang X, Cui J, Du Y, Guo Y, Wang X, Di L, Wang R. Bioengineering extracellular vesicles as novel nanocarriers towards brain disorders. Nano Res . [DOI: 10.1007/s12274-022-4913-2] [Reference Citation Analysis]
6 Zhang X, Yu Q, Zhou P, Yang S, Xia J, Deng T, Yu C. Blood-brain barrier penetrating carbon dots with intrinsic anti-inflammatory and drug-loading properties. Biomaterials Advances 2022;139:212995. [DOI: 10.1016/j.bioadv.2022.212995] [Reference Citation Analysis]
7 Sargazi S, Arshad R, Ghamari R, Rahdar A, Bakhshi A, Karkan SF, Ajalli N, Bilal M, Díez-Pascual AM. siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review. Cell Biol Int 2022. [PMID: 35830711 DOI: 10.1002/cbin.11841] [Reference Citation Analysis]
8 Djukic M, Lange P, Erbguth F, Nau R. Spatial and temporal variation of routine parameters: pitfalls in the cerebrospinal fluid analysis in central nervous system infections. J Neuroinflammation 2022;19. [DOI: 10.1186/s12974-022-02538-3] [Reference Citation Analysis]
9 Tehrani SF, Rabanel J, Legeay S, Cayon J, Riou J, Saulnier P, Marleau S, Gaëlle Roullin V, Hildgen P, Bastiat G. Tailoring PEGylated nanoparticle surface modulates inflammatory response in vascular endothelial cells. European Journal of Pharmaceutics and Biopharmaceutics 2022. [DOI: 10.1016/j.ejpb.2022.04.003] [Reference Citation Analysis]
10 Ahn SJ, Taoka T, Moon WJ, Naganawa S. Contrast-Enhanced Fluid-Attenuated Inversion Recovery in Neuroimaging: A Narrative Review on Clinical Applications and Technical Advances. J Magn Reson Imaging 2022. [PMID: 35170148 DOI: 10.1002/jmri.28117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Moradi F, Dashti N. Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2022;395:133-48. [PMID: 34982185 DOI: 10.1007/s00210-021-02196-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Charabati M, Grasmuck C, Ghannam S, Bourbonnière L, Fournier AP, Lécuyer MA, Tastet O, Kebir H, Rébillard RM, Hoornaert C, Gowing E, Larouche S, Fortin O, Pittet C, Filali-Mouhim A, Lahav B, Moumdjian R, Bouthillier A, Girard M, Duquette P, Cayrol R, Peelen E, Quintana FJ, Antel JP, Flügel A, Larochelle C, Arbour N, Zandee S, Prat A. DICAM promotes TH17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation. Sci Transl Med 2022;14:eabj0473. [PMID: 34985970 DOI: 10.1126/scitranslmed.abj0473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Zhou H, Liu Y, Long X, Qiao Y, Lee J, Peng H, Liu X, Zou C, Zheng H. Feasibility of ultrasound-induced blood-brain barrier disruption with a single-element transducer under three different frequencies in two non-human primates in vivo: Case report. J Neurosci Methods 2022;365:109383. [PMID: 34634283 DOI: 10.1016/j.jneumeth.2021.109383] [Reference Citation Analysis]
14 Hu J, Tan X, Wang D, Li Y, Liang H, Peng J, Li F, Zhou Q, Geng P, Wang S, Yu Y, Liu J. A stepwise-targeting strategy for the treatment of cerebral ischemic stroke. J Nanobiotechnology 2021;19:371. [PMID: 34789285 DOI: 10.1186/s12951-021-01118-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Nehra M, Uthappa UT, Kumar V, Kumar R, Dixit C, Dilbaghi N, Mishra YK, Kumar S, Kaushik A. Nanobiotechnology-assisted therapies to manage brain cancer in personalized manner. J Control Release 2021;338:224-43. [PMID: 34418523 DOI: 10.1016/j.jconrel.2021.08.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
16 Lynch MJ, Gobbo OL. Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders. Nanomaterials (Basel) 2021;11:2632. [PMID: 34685073 DOI: 10.3390/nano11102632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cunha S, Forbes B, Sousa Lobo JM, Silva AC. Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels. Int J Nanomedicine 2021;16:4373-90. [PMID: 34234432 DOI: 10.2147/IJN.S305851] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
18 Mojarad-Jabali S, Farshbaf M, Walker PR, Hemmati S, Fatahi Y, Zakeri-Milani P, Sarfraz M, Valizadeh H. An update on actively targeted liposomes in advanced drug delivery to glioma. Int J Pharm 2021;602:120645. [PMID: 33915182 DOI: 10.1016/j.ijpharm.2021.120645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
19 Duarte JN. Neuroinflammatory Mechanisms of Mitochondrial Dysfunction and Neurodegeneration in Glaucoma. J Ophthalmol 2021;2021:4581909. [PMID: 33953963 DOI: 10.1155/2021/4581909] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
20 Gu X, Gao Y, Wang P, Wang L, Peng H, He Y, Liu Y, Feng N. Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis. J Control Release 2021;333:374-90. [PMID: 33798666 DOI: 10.1016/j.jconrel.2021.03.039] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
21 Cerqueira SR, Ayad NG, Lee JK. Neuroinflammation Treatment via Targeted Delivery of Nanoparticles. Front Cell Neurosci 2020;14:576037. [PMID: 33192321 DOI: 10.3389/fncel.2020.576037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
22 Rabanel JM, Delbreil P, Banquy X, Brambilla D, Ramassamy C. Periphery-confined particulate systems for the management of neurodegenerative diseases and toxicity: Avoiding the blood-brain-barrier challenge. J Control Release 2020;322:286-99. [PMID: 32243978 DOI: 10.1016/j.jconrel.2020.03.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]